GENB
+$0
724,160 sh
Bancel Stephane
Director, Chief Executive Officer · SEC CIK 1443340Advertisement
Buy track record
How this insider's open-market purchases have performed100%
of buys now in profit
2 up · 0 down
Avg return since buy+64.9%
Median return+64.9%
Best trade+64.9%
Worst trade+64.9%
Buys scored2
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
−15.0%
0% won · 2 trades
After 3 months
−8.1%
0% won · 2 trades
After 6 months
−20.5%
0% won · 2 trades
After 12 months
+64.6%
100% won · 2 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | MRNA | $31 | $3.19M | +1.1% | −15.0% | −8.1% | −20.5% | +64.6% | +64.9% | |
| Mar 3, 2025 | MRNA | $32 | $1.81M | +0.6% | −15.0% | −8.1% | −20.5% | +64.6% | +64.9% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 2 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$5M
2 trades
Open-market sells
$339.71M
243 trades
Net flow
−$334.71M
Net selling
Total filings
309
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstMRNA
+$0
11,271 sh
MRNA
−$228.8K
5,450 sh @ $42
MRNA
+$7.5M
688,073 sh @ $11
MRNA
Bancel Stephane, MRNA's CEO, spent $3.19M of their own money on 102,821 shares at $31, growing their stake 1%.
+$3.19M
102,821 sh @ $31
Advertisement
MRNA
Bancel Stephane, MRNA's CEO, spent $1.81M of their own money on 57,493 shares at $32, growing their stake 1%.
+$1.81M
57,493 sh @ $32
MRNA
+$0
13,233 sh
MRNA
−$198K
6,400 sh @ $31
MRNA
+$0
26,840 sh
MRNA
−$2.34M
26,351 sh @ $89
MRNA
+$0
56,736 sh
MRNA
+$0
17,893 sh
MRNA
+$26.9K
27,155 sh @ $1
MRNA
−$274.2K
2,278 sh @ $120
MRNA
−$1.39M
11,417 sh @ $121
MRNA
−$1.6M
13,094 sh @ $122
MRNA
−$45K
366 sh @ $123
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$2.96M
24,829 sh @ $119
MRNA
−$1.82M
15,171 sh @ $120
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$2.52M
20,711 sh @ $122
MRNA
−$2.36M
19,289 sh @ $122
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$601.4K
4,788 sh @ $126
MRNA
−$682.9K
5,377 sh @ $127
MRNA
−$1.08M
8,443 sh @ $128
MRNA
−$918.7K
7,115 sh @ $129
MRNA
−$1.85M
14,277 sh @ $130
MRNA
+$39.6K
40,000 sh @ $1
Frequently asked questions
How is Bancel Stephane's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from Bancel Stephane's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.